PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Tilray Brands, Inc. (TLRY.TO)
2.000.05 (2.56%)
1.90 - 2.15
0.48 - 2.54
9.88M / 2.92M (Avg.)
-0.48 | -4.19
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
-11.93%
Negative revenue growth while CRON.TO stands at 3.70%. Joel Greenblatt would look for strategic missteps or cyclical reasons.
-15.04%
Negative gross profit growth while CRON.TO is at 5.61%. Joel Greenblatt would examine cost competitiveness or demand decline.
-960.92%
Both companies show negative EBIT growth. Martin Whitman would consider macro or sector-specific headwinds.
-1383.16%
Both companies face negative operating income growth. Martin Whitman would suspect broader market or cost hurdles.
-825.75%
Both companies face declining net income. Martin Whitman would suspect external pressures or flawed business models in the space.
-782.35%
Both companies exhibit negative EPS growth. Martin Whitman would consider sector-wide issues or an unsustainable business environment.
-500.00%
Both face negative diluted EPS growth. Martin Whitman would suspect an industry or cyclical slump with heightened share issuance across the board.
5.01%
Share reduction more than 1.5x CRON.TO's 25.88%. David Dodd would see if the company is taking advantage of undervaluation to retire shares.
5.01%
Diluted share reduction more than 1.5x CRON.TO's 25.88%. David Dodd would validate if the company is aggressively retiring shares or limiting option exercises.
No Data
No Data available this quarter, please select a different quarter.
85.85%
OCF growth under 50% of CRON.TO's 234.45%. Michael Burry might suspect questionable revenue recognition or rising costs.
50.46%
FCF growth 50-75% of CRON.TO's 94.16%. Martin Whitman would see if structural disadvantages exist in generating free cash.
21610.35%
10Y CAGR of 21610.35% while CRON.TO is zero. Bruce Berkowitz would see if incremental growth can widen into a significant edge.
-58.90%
Negative 5Y CAGR while CRON.TO stands at 204.60%. Joel Greenblatt would push for a turnaround plan or reevaluation of the company’s product line.
-34.59%
Negative 3Y CAGR while CRON.TO stands at 41.58%. Joel Greenblatt would look for missteps or fading competitiveness that hurt sales.
83.84%
10Y OCF/share CAGR under 50% of CRON.TO's 199.63%. Michael Burry would worry about a persistent underperformance in cash creation.
96.51%
5Y OCF/share CAGR is similar to CRON.TO's 106.62%. Walter Schloss might see parallel cost profiles or expansions producing comparable cash flow.
93.36%
3Y OCF/share CAGR at 75-90% of CRON.TO's 115.92%. Bill Ackman would press for improvements in margin or overhead to catch up.
-1432.24%
Both face negative decade-long net income/share CAGR. Martin Whitman would suspect a shrinking or highly disrupted sector.
-4510.94%
Negative 5Y net income/share CAGR while CRON.TO is 66.60%. Joel Greenblatt would see fundamental missteps limiting profitability vs. the competitor.
-1077.29%
Both companies show negative 3Y net income/share growth. Martin Whitman suspects macro or sector-specific headwinds in the short run.
1098.12%
10Y equity/share CAGR at 75-90% of CRON.TO's 1410.50%. Bill Ackman would push for either higher ROE or more earnings retention to catch the competitor.
-52.70%
Both show negative equity/share growth mid-term. Martin Whitman suspects cyclical or structural challenges for each company.
-68.46%
Both show negative short-term equity/share CAGR. Martin Whitman suspects an industry slump or unprofitable expansions for both players.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-8.31%
Firm’s AR is declining while CRON.TO shows 23.99%. Joel Greenblatt sees stronger working capital efficiency if sales hold up.
-0.98%
Inventory is declining while CRON.TO stands at 21.79%. Joel Greenblatt sees potential cost and margin benefits if sales hold up.
-18.81%
Negative asset growth while CRON.TO invests at 1.85%. Joel Greenblatt checks if the competitor might capture more market share unless our returns remain higher.
-25.50%
Both erode book value/share. Martin Whitman suspects a difficult environment or poor capital deployment for both players.
-7.99%
We’re deleveraging while CRON.TO stands at 10.68%. Joel Greenblatt considers if we gain a balance-sheet advantage for potential downturns.
41.67%
R&D growth drastically higher vs. CRON.TO's 17.15%. Michael Burry fears near-term margin erosion unless breakthroughs are imminent.
-14.49%
We cut SG&A while CRON.TO invests at 8.16%. Joel Greenblatt sees a short-term margin benefit but wonders if the competitor invests for future gains.